ZITHROMAX FOR INTRAVENOUS INJECTION POWDER FOR SOLUTION

Riik: Kanada

keel: inglise

Allikas: Health Canada

Toimeaine:

AZITHROMYCIN

Saadav alates:

PFIZER CANADA ULC

ATC kood:

J01FA10

INN (Rahvusvaheline Nimetus):

AZITHROMYCIN

Annus:

500MG

Ravimvorm:

POWDER FOR SOLUTION

Koostis:

AZITHROMYCIN 500MG

Manustamisviis:

INTRAVENOUS

Ühikuid pakis:

5ML

Retsepti tüüp:

Prescription

Terapeutiline ala:

OTHER MACROLIDES

Toote kokkuvõte:

Active ingredient group (AIG) number: 0126072006; AHFS:

Volitamisolek:

APPROVED

Loa andmise kuupäev:

1999-04-15

Toote omadused

_ZITHROMAX (azithromycin dihydrate) - Product Monograph _
_Page 1 of 86_
PRODUCT MONOGRAPH
INCLUDING PATIENT MEDICATION INFORMATION
PR
ZITHROMAX
®
azithromycin dihydrate
Azithromycin tablets USP, 250 mg, 600 mg for oral use
Azithromycin USP, 100 mg/5 mL, 200 mg/5 mL for oral suspension
Azithromycin USP, 500 mg/vial, 100 mg/mL when reconstituted for
Injection
Antibacterial Agent
Pfizer Canada ULC
17300 Trans-Canada Highway
Kirkland, Quebec H9J 2M5
Pfizer Canada ULC, Licensee
© Pfizer Canada ULC 2022
Product Licensed from Pliva, Zagreb, Croatia
Date of Initial Authorization:
May 13, 1994
Date of Revision:
April 27, 2023
Submission Control Number: 270217
_ _
_ZITHROMAX (azithromycin dihydrate) - Product Monograph_
_ _
_Page 2 of 86_
RECENT MAJOR LABEL CHANGES
7 WARNINGS AND PRECAUTIONS, 7.1 Special Populations, 7.1.1
Pregnant Women
04/2023
TABLE OF CONTENTS
SECTIONS OR SUBSECTIONS THAT ARE NOT APPLICABLE AT THE TIME OF
AUTHORIZATION ARE NOT LISTED.
RECENT MAJOR LABEL
CHANGES............................................................................................
2
TABLE OF CONTENTS
..............................................................................................................
2
PART I: HEALTH PROFESSIONAL INFORMATION
.....................................................................
4
1
INDICATIONS
..............................................................................................................
4
1.1
Pediatrics
..........................................................................................................
6
1.2
Geriatrics...........................................................................................................
7
2
CONTRAINDICATIONS
.................................................................................................
7
4
DOSAGE AND
ADMINISTRATION.................................................................................
7
4.1
Dosing Considerations
.......................................................................................
7